CLOs on the Move

Cooldimi

www.cooldimi.com

 
Cooldimi is a stealth mode startup based in Silicon Valley. Cooldimi uses Artificial Intelligence and Chatbot frameworks to improve Customer Experience (CX). Cooldimi believes that Artificial Intelligence and machine learning enabled Chatbots will not be able to replace human intelligence in the near future. Cooldimi blends artificial intelligence with human intelligence to assist humans in improving overall customer experience. Cooldimi is focused on enabling Conversational Computing.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Hobbit Travel

Hobbit Travel is a Des Plaines, IL-based company in the Business Services sector.

Primasun

A joint venture from Verily and Resmed, Primasun is focused on developing new solutions that enable healthcare providers to more efficiently identify, diagnose, treat, and manage individuals with sleep apnea and other breathing related sleep disorders.

Ixio Corporation

Ixio Corporation is a Seattle, WA-based company in the Business Services sector.

Students For Liberty

Students For Liberty is an international libertarian non-profit organization with origins in the United States.

Vansen Pharma, Inc.

Vansen Pharma Inc. is a specialty pharmaceutical company focused on broad therapeutic areas that are anticipated to grow and present an opportunity for major expansion.  Vansen will expand its commercial presence by adding complimentary products through in-licensing, co-promotion and acquisitions, resulting in a comprehensive product portfolio.  With its US based sales force, Vansen can better serve the increasing healthcare needs of patients and enhance growth.  Vansen's current product portfolio of anti-infectives, including Factive®, Spectracef® and Cefditoren Pivoxil®, provides a strong and stable revenue base from which to grow and expand our company. Our experienced management team is aggressively pursuing acquisitions of accretive specialty products, including legacy drugs and cash flow positive healthcare companies.  We look forward to executing our growth strategy and creating lasting shareholder value for our investors.